<DOC>
	<DOCNO>NCT00172094</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety single oral dose NPS 1776 acute treatment migraine pain associate symptom .</brief_summary>
	<brief_title>Safety Efficacy NPS 1776 Acute Treatment Migraine Headaches</brief_title>
	<detailed_description>Migraine , common cause recurrent severe disable headache , diagnose basis clinical history intermittent headache autonomic , constitutional , neurologic disturbance . Many antiepileptic drug ( AEDs ) demonstrate efficacy acute and/or prophylaxis therapy migraine , even though mechanism action various AEDs poorly understood . NPS 1776 , isovaleramide , neutral aliphatic amide . The mechanism NPS 1776 exert therapeutic action nonclinical animal model disease unclear . The true many antiepileptic market today . NPS 1776 appear bind directly various CNS receptor center , although show broad range anticonvulsant activity multiple animal model seizures . This broad profile anticonvulsant activity similar valproic acid ( VPA ) , may also predict NPS 1776 efficacy treatment migraine .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Diagnosis migraine least year prior screen . 2 . Experiences 210 migraine headache per month ( least 24 hour episode ) 15 headache day per month 3 month prior screen . 3 . Ability willingness arrive investigator 's center within 1 hour ( Â±5 min ) migraine pain onset ( define pain consistent subject 's usual migraine least moderate severity ) . 4 . Ability willingness abstain take medication allow protocol meet phone checkin criterion . 5 . Ability willingness undergo comprehensive urine toxicology screen licit illicit drug . 6 . Ability willingness complete migrainehistory diary screening treatment study drug migrainetreatment diary discharge remainder 24hour period follow studydrug treatment . 1 . Unstable uncontrolled significant metabolic , hepatic , renal , hematological , pulmonary , gastrointestinal , urological , neurological ( except migraine headache ) , psychiatric disorder . 2 . Severe acute cardiovascular cerebrovascular disease , uncontrolled hypertension , basilar hemiplegic migraine . 3 . History hypersensitivity , allergy , nonresponse valproic acid . 4 . Have take VPA AED 30 day prior screen , take migraine prophylaxis treatment stable dose propranolol tricyclic antidepressant . 5 . Migraine attack investigator 's opinion associate intractable nausea and/or vomit . 6 . Any acute chronic condition investigator 's opinion would limit subject 's ability complete and/or participate clinical study would place subject increase risk . 7 . Have newly start change dose either feverfew magnesium ( 200 mg , amount common daily supplement ) within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Migraine</keyword>
</DOC>